Gwynn C M
Arch Dis Child. 1974 Aug;49(8):636-40. doi: 10.1136/adc.49.8.636.
Two branches of a family suffering from hereditary angioneurotic oedema underwent trials of therapy of ε-amino caproic-acid (EACA) to ascertain the optimum dosage required to alleviate symptoms without giving rise to unpleasant side effects. It was found that children under 11 years tolerated 3 g/day and patients over 11 years 6 g/day without side effects, but with incomplete control of symptoms in some of the patients. However, if the dose was doubled for a period of less than 4 days during times of expected and experienced trauma, better control was achieved and unpleasant muscle cramps were not experienced. These doses, though effective, were much smaller than those used in previous studies.
两个患有遗传性血管性水肿的家族分支接受了ε-氨基己酸(EACA)治疗试验,以确定缓解症状且不产生不良副作用所需的最佳剂量。结果发现,11岁以下儿童耐受3克/天,11岁以上患者耐受6克/天,均无副作用,但部分患者症状控制不完全。然而,如果在预期和经历创伤期间将剂量加倍不到4天,则可实现更好的控制,且未出现令人不适的肌肉痉挛。这些剂量虽然有效,但比以前研究中使用的剂量小得多。